AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 51
- Registration Number
- NCT00241449
- Locations
- 🇬🇧
Research Site, York, United Kingdom
Open Label Arimidex in Gynecomastia
Phase 2
Completed
- Conditions
- Gynecomastia
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT00241436
- Locations
- 🇺🇸
Research Site, Jacksonville, Florida, United States
Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
Phase 3
Completed
- Conditions
- NSAIDsUpper GI Symptoms
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 556
- Registration Number
- NCT00241527
- Locations
- 🇬🇧
Research Site, Yoxall, United Kingdom
🇸🇪Sweden, Gävle, Sweden
Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
Phase 3
Completed
- Conditions
- GERD
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 808
- Registration Number
- NCT00241540
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
Phase 3
Completed
- Conditions
- NSAIDsUpper GI Symptoms
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 276
- Registration Number
- NCT00241553
- Locations
- 🇬🇧
Research Site, Yoxall, United Kingdom
Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
Phase 3
Completed
- Conditions
- GERD
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 334
- Registration Number
- NCT00241514
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients
Phase 3
Completed
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 140
- Registration Number
- NCT00241501
- Locations
- 🇮🇹
Research Site, Roma, Italy
Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy
Phase 2
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00241475
- Locations
- 🇫🇮
Research Site, Helsinki, Finland
Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients
Terminated
- Conditions
- Breast Cancer
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT00241462
- Locations
- 🇳🇱
Research Site, Zwolle, Netherlands
Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00241423
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath